Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases, reported fourth-quarter financial results. Q4 2025 results at Minerva Neurosciences, Inc (NERV) showed a adjusted loss of $0.64 per share.
The company’s lead product candidate is roluperidone, which is being developed for the treatment of negative symptoms in patients with schizophrenia. Minerva continues to advance its pipeline of therapies targeting neurological and psychiatric disorders.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.